Form 4: Cytokinetics Director Wendell Wierenga Reports Acquisition of Stock and Options

Director Wendell Wierenga reports acquisition of Cytokinetics stock and options, including restricted stock units and non-qualified stock options, as per Form 4 filing.

Summary

• Wendell Wierenga, a director of Cytokinetics Inc., filed a Form 4 detailing changes in beneficial ownership.
• On May 14, 2025, Wierenga acquired 7,333 shares of common stock through restricted stock units (RSUs) at a price of $0.
• These RSUs will vest in one installment on the earlier of the one-year anniversary of the grant date or the date of the issuer's annual meeting of stockholders for the subsequent calendar year, contingent upon continuous service as a director.
• Additionally, Wierenga acquired 10,880 non-qualified stock options with an exercise price of $30.
• These options vest monthly in equal installments over a year, also contingent upon continuous service as a director, and expire on May 13, 2035.
• Following these transactions, Wierenga beneficially owns 32,181 shares of common stock and 10,880 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock and option grants to a director, which is neither overtly positive nor negative.

Positives

• The acquisition of stock and options by a director may signal confidence in the company's future prospects.

Future Outlook

The vesting of RSUs and stock options is contingent upon the director's continuous service, suggesting an ongoing commitment to the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment if interpreted as a sign of director confidence.

Key Dates

Keywords

Form 4, beneficial ownership, Cytokinetics, director, stock options, restricted stock units, RSUs, Wendell Wierenga